IntelGenx Corp.

Investors

Press Releases

  • 03/04/2010
    IntelGenx and Cannasat Announce Letter of Intent for Relivar License
  • 02/08/2010
    IntelGenx Receives FDA Complete Response Letter CPI-300
  • 01/25/2010
    IntelGenx Enters Strategic Manufacturing Partnership for VersaFilm Technology
  • 01/22/2010
    IntelGenx Grants Options to IR Firm
  • 01/21/2010
    IntelGenx Receives Notice of Allowance for Bupropion Patent
  • 01/11/2010
    IntelGenx Announces Manufacturing Site Change for CPI-300
  • 11/17/2009
    IntelGenx Achieves Positive Bioequivalence Results With Novel Anti-Migraine Film
  • 11/10/2009
    IntelGenx Reports Results For the Third Quarter and Nine Months Ended September 30, 2009
  • 10/06/2009
    IntelGenx Determines Exercise Price of Stock Options to IR Firm
  • 10/01/2009
    IntelGenx Strengthens Investor Relations Activities
  • 09/04/2009
    IntelGenx Technologies Corp. Completes Additional Private Placement
  • 08/31/2009
    IntelGenx Technologies Corp. Announces Shareholder Call
  • 08/21/2009
    IntelGenx Corp. Comments on CPI-300 Patent Infringement Complaint
  • 08/14/2009
    IntelGenx Reports Results for the Second Quarter and Six Months Ended June 30, 2009
  • 07/29/2009
    IntelGenx Technologies Corp. Files Preliminary Short Form Prospectus; IntelGenx Completes Additional Private Placement
  • 07/14/2009
    IntelGenx Technologies Corp. Announces Closing of Private Placement
  • 06/23/2009
    IntelGenx Corp. Announces FDA Acceptance for Filing of NDA for CPI-300 Antidepressant
  • 05/19/2009
    IntelGenx Corp. and Circ Pharma to Commence Phase 1 Proof-of-Concept Study of CRES Pravastatin, a Novel Low Dose Formulation Containing Pravastatin for the Treatment of Hyperlipidemia
  • 05/13/2009
    IntelGenx Reports Results for the First Quarter of 2009
  • 04/20/2009
    Positive Bioequivalence Results for IntelGenx Developed Product
  • 04/15/2009
    IntelGenx Announces Appointment of New Director
  • 04/14/2009
    Cannasat and IntelGenx Announce Positive Phase 1(b) Results Improved buccal tablet outperforms oral dronabinol
  • 04/07/2009
    IntelGenx Corp. and Cary Pharmaceuticals file NDA for CPI-300 antidepressant
  • 03/25/2009
    IntelGenx Technologies Corp. Announces 2008 Annual Financial Results
  • 01/28/2009
    Cannasat Therapeutics and IntelGenx Corp. Reach Key Milestone
  • 01/19/2009
    IntelGenx Corp. and Circ Pharma Ltd announced today a partnership to develop and commercialise a novel drug for the treatment of hyperlipidemia.
  • 11/12/2008
    IntelGenx Reports Results for the Nine Months Ended September 30, 2008
  • 10/10/2008
    IntelGenx Corp. set to file NDA for antidepressant
  • 09/05/2008
    IntelGenx Welcomes New Chief Financial Officer, Paul Simmons
  • 07/30/2008
    IntelGenx Corp. and Cary Pharmaceuticals Inc. Announce Successful End-of-Phase II Meeting with FDA for Development of their Antidepressant CPI-300
  • 06/03/2008
    IntelGenx Technologies Corp. Engages Auctus Capital Partners Inc. To Perform Investor Relations Activities
  • 05/22/2008
    IntelGenx Technologies Corp. Approved for trading on the TSX-Venture Exchange
  • 04/14/2008
    IntelGenx Corp. Forms Strategic Alliance with Dava Pharmaceuticals to Develop Cardiovascular Product Addressing a U.S. Market of $1.0 Billion
  • 04/07/2008
    IntelGenx Corp. and Cary Pharmaceuticals Confirm Agreement to Develop a Novel Antidepressant
  • 03/28/2008
    IntelGenx Technologies Corp. announces closing of private placement
  • 01/07/2008
    IntelGenx Corp. Forms Strategic Agreement with Azur Pharma to Develop Prenatal Vitamin Supplements Addressing a U.S. Market of $250 million
  • 11/21/2007
    IntelGenx Technologies Corp. Reports Financial Results for the First Nine Months of 2007
  • 11/05/2007
    IntelGenx Corp. and Cary Pharmaceuticals Sign a Definitive Agreement to Develop a Novel Antidepressant
  • 10/31/2007
    IntelGenx Technologies Corp. Will Present Recent Achievements and Market Opportunities at Rodman & Renshaw’s 9th Annual Healthcare Conference, November 7, 2007
  • 09/10/2007
    IntelGenx Proprietary Delivery Technology Tested in Cannasat Therapeutics' Phase I Study for Drug Treatment for Neuropathic Pain
  • 08/29/2007
    IntelGenx Technologies Corp. Reports Revenues Increased by More Than 124% for the First Six Months of 2007
  • 08/09/2007
    IntelGenx Technologies Corp. Appoints New Chief Financial Officer
  • 08/07/2007
    IntelGenx Technologies Corp. Appoints New Vice President of Business Development
  • 07/12/2007
    IntelGenx Technologies Corp. Engages Consulting for Strategic Growth 1 for Investor and Public Relations
  • 05/29/2007
    Senior Executive Joins IntelGenx Technologies Corp. Management Team
  • 05/24/2007
    IntelGenx Technologies Corporation has completed the sale of secured convertible debentures in an aggregate principal amount of U.S. $1.5 million to certain institutional and accredited investors.
  • 05/03/2007
    IntelGenx Technologies Corporation and Cary Pharmaceuticals today announced that the pilot clinical trial of QuitPak showed positive intermediate results.
  • 04/30/2007
    IntelGenx Technologies Corporation today announced that the company signed a licensing and development agreement with a major US pharmaceutical company for the development and commercialization of a generic product.
  • 03/26/2007
    IntelGenx Technologies Corp. and Cary Pharmaceuticals Inc. announce enrollment of Phase I Pilot Study for QuitPak®
  • 03/20/2007
    Cannasat Therapeutics and IntelGenx enter into agreement to develop cannabinoid-based products for the treatment of mood disorders such as anxiety and depression
  • 01/30/2007
    IntelGenx Technologies Corp. enters into consulting agreement with Dr. David Coffin-Beach
  • 01/05/2007
    IntelGenx is developing two platform technologies; one is a Tri-Layer Tablet technology that allows for the development of oral controlled release products, and the second is a breakthrough Quick Release Wafer technology that is intended for the rapid delivery of pharmaceutically active substances
  • 11/14/2006
    Cannasat Therapeutics and IntelGenx Enter into a Collaborative Agreement to Develop Novel Cannabinoid-based Products Based on Proprietary Drug Delivery Technologies
  • 4/28/06
    Completed $1.35 million private placement
  • 11/28/05
    Entered into development agreement with Cary Pharmaceuticals